ストックスクリーナーアプリを入手
130.36
0.97%
-1.28
アフターアワーズ：
130.43
0.07
+0.05%
前日終値:
$131.64
開ける：
$131.53
24時間の取引高:
1.22M
Relative Volume:
0.86
時価総額：
$275.38B
収益：
$53.40B
当期純損益:
$13.68B
株価収益率:
18.93
EPS:
6.8864
ネットキャッシュフロー:
$16.89B
1週間 パフォーマンス:
-0.81%
1か月 パフォーマンス:
+5.98%
6か月 パフォーマンス:
+17.26%
1年 パフォーマンス:
+15.23%
1日の値動き範囲:
$130.28
$131.54
1週間の範囲:
$130.28
$132.33
52週間の値動き範囲:
$96.06
$133.55
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases - GlobeNewswire Inc.
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm
Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds - The Globe and Mail
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.51%
大文字化:
|
ボリューム (24 時間):